Britain was the first to approve the shot for emergency use on Dec.
3, followed by Canada and the U.S. Food and Drug Administration.
"In Britain, 140,000 people have been vaccinated by now and the
tolerability data are exactly as we have shown in our clinical
trial," Chief Medical Officer Oezlem Tuereci said in a webcast call
with German Chancellor Angela Merkel.
She said side effects have been mild to moderate and short-lived and
similar to those typically seen in other commonly used vaccines.
The German biotech firm's Chief Executive Ugur Sahin said in the
call that he was confident that normal life could resume by next
winter.
(Reporting by Ludwig Burger; editing by Thomas Seythal)
[© 2020 Thomson Reuters. All rights
reserved.]
Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |